DecisionPoint Financial’s Novo Nordisk NVO Stock Holding History

DecisionPoint Financial’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-66	Closed	-$2.43K	–	1457
2026 Q1	$2.43K	Hold	66	–	–	﹤0.01%	267
2025 Q4	$3.36K	Hold	66	–	–	﹤0.01%	291
2025 Q3	$3.91K	Hold	66	–	–	﹤0.01%	189
2025 Q2	$4.61K	Hold	66	–	–	﹤0.01%	184
2025 Q1	$4.58K	Hold	66	–	–	﹤0.01%	182
2024 Q4	$5.68K	Hold	66	–	–	﹤0.01%	187
2024 Q3	$7.86K	Hold	66	–	–	﹤0.01%	171
2024 Q2	$8.75K	Hold	66	–	–	﹤0.01%	158
2024 Q1	$8.37K	Hold	66	–	–	﹤0.01%	168
2023 Q4	$6.83K	Buy	66 +30	+83%	+$2.97K	﹤0.01%	145
2023 Q3	$3.27K	Hold	36	–	–	﹤0.01%	168
2023 Q2	$2.91K	Hold	36	–	–	﹤0.01%	156
2023 Q1	$2.87K	Hold	36	–	–	﹤0.01%	159
2022 Q4	$2.44K	Buy	+36	New	+$2.11K	﹤0.01%	140

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

DecisionPoint Financial's NVO Position: Q2 2026 in Review

DecisionPoint Financial sold out of Novo Nordisk (NVO) in Q2 2026, closing a stake of 66 shares — an estimated $2.43K sold.

DecisionPoint Financial first reported a position in NVO in Q4 2022 and held it in 14 quarters. The position peaked at $8.75K in Q2 2024. 1,354 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

DecisionPoint Financial reported no remaining Novo Nordisk position as of Q2 2026 after selling out during the quarter.
DecisionPoint Financial sold 66 Novo Nordisk shares in Q2 2026, an estimated $2.43K.
DecisionPoint Financial first reported a position in Novo Nordisk in Q4 2022 and held it in 14 quarters.
DecisionPoint Financial's Novo Nordisk position peaked at $8.75K in Q2 2024.
1,354 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on DecisionPoint Financial's 13F filing for Q2 2026, filed 5 Aug 2026.